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Antimicrobial efficacy of the combination of chlorhexidine
digluconate and dexpanthenol
AntiseptischeWirksamkeit der Kombination von Chlorhexidindigluconat
mit Dexpanthenol
Abstract
Objective: The objective of this standardised experimental study was
to investigate the antimicrobial efficacy of the combination of
Axel Kramer1
Ojan Assadian2
chlorhexidine digluconate (CHX) and the anti-inflammatory pro-vitamin
Torsten
Koburger-Janssen3
dexpanthenol, which stimulates wound-healing, in the form of Bepan-
then® AntisepticWound Cream, in order to rule out possible antagonistic
combination effects of CHX and the alcohol analogue of pantothenic
acid (vitamin B5) dexpanthenol.
1 Institute of Hygiene and
Environmental Medicine,Method: Testing was carried out using the quantitative suspension test
at conditions simulating wound bio-burden. Test strains included Entero- University Medicine
Greifswald, Germanycoccus hirae (ATCC 10541) and Candida albicans (ATCC 10231) in
accordance with the standard methods of the German Hygiene and
2 Institute for Skin Integrity and
Infection Prevention,
Microbiology Society with the following three organic challenges: i) cell
culture medium MEM with Earle’s salts, L-glutamine and 10% foetal University of Huddersfield,
UKcalf serum (CCM); ii) 10% sheep’s blood; iii) or a mixture of 4.5% albu-
min, 4.5% sheep’s blood and 1% mucin. For methodological reasons,
3 Hygiene-North GmbH,
Greifswald, Germany
the wound creamwas tested as a 55% dilution, prepared with 1% Tween
80 (equivalent to a content of 0.275% CHX instead of 0.5% as in the
original preparation). CHX 0.275% was tested as control in an aqueous
solution and in 1% Tween 80. Additionally, 1% Tween 80 was tested in
order to rule out an interfering effect of the dilution medium. A com-
bination of 3% Tween 80, 3% saponin, 0.1% histidine, 0.3% lecithin,
0.5% Na-thiosulphate and 1% ether sulphate was identified as themost
appropriate neutraliser during the experiments.
Results: Exposed to CCM or 10% sheep’s blood, the tested wound cream
fulfilled the requirements for a wound antiseptic against both test spe-
cies with ≥3 log reduction at 10 minutes. Even at the the worst-case
challenge test with 4.5% albumin, 4.5% sheep’s blood and 1% mucin,
the requirement for a ≥3 log reduction wasmet after 24 hours of expos-
ure. Interestingly, the aqueous solution of 0.275% CHX tested as control
did not achieve the antimicrobial efficacy of the combination of CHX
and 5% dexpanthenol. 1% Tween 80 was ineffective against both test
species.
Conclusion: Bepanthen® Antiseptic Wound Cream achieves the in vitro
bactericidal and fungicidal efficacy required for a wound antiseptic under
three different challenges, despite dilution to 55% of the original pre-
paration. So far, the addition of dexpanthenol was intended to support
wound healing. However, our results indicate that the antiseptic efficacy
of CHX is synergistically increased by adding 5% dexpanthenol. Acknow-
ledging the antimicrobial and residual efficacy of CHX, and bearing in
the mind the contraindications to CHX (allergy and anaphylaxis), the
tested wound cream should be regarded as better suitable to be used
as wound antiseptic than preparations on basis of CHX alone.
Keywords: chlorhexidine digluconate, dexpanthenol, enhancement of
microbiocidal efficacy, wound antiseptic
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Zusammenfassung
Zielsetzung: In der vorliegenden Untersuchung sollte die mikrobiozide
Wirksamkeit der Kombination von Chlorhexidindigluconat (Chx) mit dem
antiinflammatorisch wirksamen und die Wundheilung stimulierenden
Provitamin Dexpanthenol in Form von Bepanthen® Antiseptische
Wundcreme geprüft werden, um mögliche antagonistische Kombinati-
onseffekte von Chxmit dem Analogon der Panthotensäure (Vitamin B5)
Dexpanthenol auszuschließen.
Methode: Die Testung erfolgte im quantitativen Suspensionstest mit
den Teststämmen Enterococcus hirae ATCC 10541 und Candida albi-
cans ATCC 10231 gemäß den Standardmethoden der Deutschen Ge-
sellschaft für Hygiene und Mikrobiologie mit den drei Belastungen
Zellkulturmedium MEM mit Earle-Salzen, L-Glutamin und 10% fetalem
Kälberserum (CCM), 10% Schafblut bzw. der Mischung 4,5% Albumin,
4,5%Schafblut und1%Mucin. DieWundcremewurde ausmethodischen
Gründen als 55%ige Verdünnung, hergestellt mit 1% Tween 80, geprüft
(entspricht einem Gehalt von 0,275% Chx anstatt von 0,5% wie im Ori-
ginalpräparat). Zum Vergleich wurde Chx 0,275% als wässrige Lösung
sowie in 1% Tween 80 geprüft. Zusätzlich wurde 1% Tween 80 geprüft,
um eine Eigenwirkung auszuschließen. Zur Ausschaltung der mikrobio-
statischen Nachwirkung wurde die Kombination 3% Tween 80, 3% Sa-
ponin, 0,1% Histidin, 0,3% Lecithin, 0,5% Na-Thiosulfat und 1% Ether-
sulfat verwendet, die sich in allen Versuchen als am effektivsten zur
Neutralisation erwies.
Ergebnisse: Bei Belastung sowohl mit CCM als auch mit 10% Schafblut
erfüllt die Wundcreme gegen beide Testspecies die Anforderungen an
ein Wundantiseptikum mit ≥3 lg innerhalb von 10 min. Bei Testung der
worst case-Belastung 4,5% Albumin, 4,5% Schafblut und 1%Mucin wird
die Anforderung ≥3 lg innerhalb von 24 h erfüllt.
Die zum Vergleich geprüfte wässrige Lösung von 0,275% Chx erreicht
nicht die Wirksamkeit der Wundcreme. Die Wirksamkeit der Lösung
von Chx in 1% Tween 80 ist im Vergleich zur wässrigen Lösung noch
geringer. Die 1%ige Lösung von Tween 80 war gegen beide Prüforganis-
men unwirksam.
Schlussfolgerung: Bepanthen® Antiseptische Wundcreme erreicht die
in vitro für ein Wundantiseptikum geforderte bakterizide und levurozide
Wirksamkeit bei drei unterschiedlichen Belastungen einschließlich einer
worst-case-Situation trotz der Verdünnung auf 55% des Originalpräpa-
rats. Die Ergebnisse sprechen dafür, dass durch den Zusatz von 5%
Dexpanthenol die antiseptische Wirksamkeit von Chx in vitro erhöht
wird. Durch den Zusatz von Dexpanthenol eine Unterstützung der
Wundheilung zu erwarten.
Unter Berücksichtigung neuerer Befunde aus demSchrifttum zurmikro-
bioziden und remanenten Wirksamkeit von Chx und bei Beachtung der
Kontraindikationen für Chx (Allergie und Anaphylaxie) ist dieWundcreme
zur Wundantiseptik als geeignet anzusehen.
Schlüsselwörter: Chlorhexidindigluconat, Dexpanthenol, Verstärkung
der mikrobioziden Wirksamkeit, Wundantiseptik
Introduction
Pantothenic acid (vitamin B5) and its biologically active
precursor D-dexpanthenol (panthenol, pantothenol) acti-
vates the proliferation of fibroblasts, promotes the forma-
tion of collagen fibres, stimulates the regeneration of
damaged tissue, and has an anti-inflammatory and anti-
oxidative effect [1], [2], [3], [4], [5], [6]. D-dexpanthenol
has therefore been combined in topical antimicrobial
preparations, both antiseptics and antibiotics, intended
to be used on wounds [7]. Although the addition of dex-
panthenol into antimicrobial wound preparations is aimed
to support wound healing, it is not known if the compound
may interfere with the antimicrobial action of various
antimicrobial compounds. Indeed, an inhibiting effect
would particularly have a detrimental effect on antibiotics,
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as their minimum inhibitory concentrationmay reach sub-
therapeutic dosages. In general, and specifically there-
fore, the topical application of systemic antibiotics should
be opposed, primarily because of the risk of development
of bacterial resistance [8], [9]. The WHO also reached
the following conclusion: “The use of topical antibiotics
and washing wounds with antibiotic solutions are not re-
commended” [10].
As an alternative to the use of systemic antibiotics in
wound antiseptics, therefore, the combination of the an-
tiseptic agent chlorhexidine digluconate (CHX) with dex-
panthenol was introduced in the form of Bepanthen®
Antiseptic Wound Cream. CHX appears to be relatively
safe with little effect on the wound healing process [9].
However, although the use of an antiseptic in a wound
healing ointmentmay be superior to the use of antibiotics,
still the question of possible interactions between the
two active compounds remains unknown. Therefore, the
purpose of the present study was to compare the antimi-
crobial efficacy of the combination of CHX and dexpan-
thenol in simulated wound conditions as contained in
Bepanthen® Antiseptic Wound Cream, with the efficacy
of CHX in an identical concentration dissolved in Tween
80 or dissolved in water, in order to rule out possible in-
terference.
Method
Bepanthen® Antiseptic Wound Cream (Bayer Vital GmbH,
Leverkusen, Germany) contains 5mg CHX as the antisep-
tic active ingredient with the addition of 50 mg dexpan-
thenol per g which has anti-inflammatory and wound-
healing properties. Excipients contained in the formulation
are macrogol stearate 1500, glycerol monostearate
40-55, cetomacrogol 1000, liquid paraffin, cetyl stearyl
alcohol (Ph.Eur.), dimethicone 1000, glycerol 85%, hard
paraffin, hyetellose and purified water. Since the antimi-
crobial wound cream could not be tested undiluted as an
ointment, a 55% dilution was further tested in a quanti-
tative suspension test. The dilution was prepared with
1% Tween 80 (Merck KGaA, Art.-Nr. 8.22187.2500, Lot
S6698387). Instead of the original ointment preparation
contain 0.5% CHX, the 55% dilution had a CHX content
of 0.275%. CHX (Sigma-Aldrich, Product number C9394,
Batch BCBK1284V) was tested in an identical concentra-
tion to that in the diluted wound cream, i.e. 0.275%, once
as an aqueous solution and additionally in 1% Tween 80.
The 1% Tween 80 solution used to dilute the cream was
also tested alone in order to rule out an interfering effect
of the dilution solution.
Testing was carried out using the quantitative suspension
test for bactericidal and fungicidal efficacy in accordance
with the standard methods of the German Society for
Hygiene and Microbiology (DGHM) [11]. A suspension of
test organisms in a solution of the interfering substance
was mixed with a sample of the test product. Enterococ-
cus hirae (ATCC 10541) was used as test bacterium and
Candida albicans (ATCC 10231) was used to determine
the levoricidal efficacy. To simulate wound conditions and
wound treatment, exposure times of 10 minutes, 30
minutes, 1 hour, and 24 hours were selected. Three dif-
ferent organic challenges were tested: i) Cell culture me-
dium (CCM)MEMwith Earle’s salts, L-glutamine and 10%
foetal calf serum; ii) 10% sheep’s blood; and iii) 4.5% al-
bumin, 4.5% sheep’s blood and 1% mucin.
All tests were performed in duplicate for each contact
time and test organism. At the end of the contact time,
an aliquot of 0.5 mL was obtained; the microbicidal
activity in the sample was immediately neutralized. The
number of surviving test organisms in each sample was
determined by plating aliquots of the neutralized test
suspensions and its dilutions. The reduction was calcu-
lated in relation to a control sample containing water in-
stead of the test product (water control, WSH control).
The experimental conditions, the non-toxicity of the
neutralizer and the dilution-neutralization method were
all validated according to the DGHM standard methods:
Water control (WSH), method validation (dilution-neutral-
ization method) and non-toxicity of the used neutralizer
3% Tween 80 + 3% saponin + 0.1% histidine + 0.3% le-
cithin + 0.5% sodium thiosulphate + 1% ether sulphate.
Results
When exposed to both CCM and 10% sheep’s blood, the
tested 55%diluted wound ointmentmet the requirements
for a wound antiseptic against both E. hirae and
C. albicans with ≥3 log within 10 minutes [12]. In the
worst-case challenge test with 4.5% albumin, 4.5%
sheep’s blood, and 1% mucin, the requirement for a ≥3
log reduction hours was met within 24 hours, which also
corresponds to a real-life situation (Table 1).
The corresponding aqueous solution of 0.275% CHX did
not achieve the efficacy of the wound ointment. Antiseptic
efficacy against E. hirae could not be achieved with ex-
posure to 4.5% albumin + 4.5% sheep’s blood + 1% mu-
cin (Table 1). The efficacy of the solution of CHX in 1%
Tween 80with exposure to 4.5% albumin + 4.5% sheep’s
blood + 1% mucin was even lower compared to the
aqueous solution (Table 1). As expected, the 1% Tween
80 solution was ineffective against both test organisms.
Discussion
Our results indicate that the combination of 5% dexpan-
thenol and CHX showed no antimicrobial antagonisms.
Testing was carried out in accordance with the standard
method of the German Society for Hygiene and Microbio-
logy for the suspension test [11], however, with some
modifications dictated by format of the test composition.
Instead of S. aureus, E. faecalis, and P. aeruginosa, En-
terococcus hirae ATCC 10541 was selected as test strain
as thismicroorganism has proved to be themost resistant
compared to the other species tested in parallel [13].
Furthermore, a substantially higher organic challenge
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Table 1: Reduction factors (log) of the bactericidal and fungicidal efficacy of Bepanthen® Antiseptic Wound Cream and the
reference/control preparations
was selected as proposed by the DGHM method, which
does not cover the condition of the application of antisep-
tics to wounds. CCM corresponds best to the composition
of wound fluid [14]. In order to test the effect of blood, a
mixture of 5% albumin, 4.5% sheep’s blood and 1%mucin
was used as a further challenge in accordance with the
recommendations of Assadian andKramer [15]. However,
it has to be noted that the addition of mucin is not re-
garded as essential for testing wound antiseptics. Yet, in
order to be able to assess efficacy in the case of wounds
in the region of the mouth and nasal cavity if necessary,
the addition of 1%mucin to 4.5% albumin + 4.5% sheep’s
blood was selected as a worst-case scenario in accord-
ance with the recommendations of Pitten et al. [12]. In
addition, 10% sheep’s blood was also tested as a chal-
lenge in order to take account of the draft Recommenda-
tion of the German Society of Hospital Hygiene of 2000
[16]. This took account of the current state of the art in
the selection of challenges. Unlike the standard method,
only one concentration was tested, as other dilutions
were not relevant to actual practice in relation to use as
a wound antiseptic. In order to take account of real-life
application, exposure times of 10 minutes, 30 minutes,
1 hour and 24 hours were selected. And finally, in order
to eliminate a residual bacteriostatic effect of the patho-
gen suspension inoculated from the test suspension on
to the agar, 3% Tween 80 + 3% saponin + 0.1% histidine
+ 0.3% lecithin + 0.5% sodium thiosulphate + 1% ether
sulphate were added to the preparation.
Because ofmethodological reasons, Bepanthen® Antisep-
tic Wound Cream had to be tested as a 55% dilution. The
addition of 1% Tween 80 to the ointmentmade it possible
to test the preparation as a suspension. Even greater ef-
ficacymust therefore be assumedwhen thewound cream
is used in undiluted form. As it can be deduced from the
test results for the CHX dilution in 1% Tween 80 that
Tween 80 reduces the antimicrobial efficacy of CHX, which
is in accordance with previous findings [13]. Therefore,
it may be concluded that there is an even greater efficacy
reserve for the use of the wound ointment without the
test-imposed addition of Tween 80. Whilst efficacy is
achieved within 10 minutes without the exposure to mu-
cin, the necessary exposure time was extended to
24 hours with the addition of mucin. Thus, as expected,
the addition of mucin had the greatest effect on efficacy.
In comparison, the antiseptic active substance polyhex-
anide loses its antiseptic efficacy in the presence of only
0.5% mucin [17], [18], [19]. In this context, the result
with CHX is remarkable.
The most important finding of the present study is that
the antimicrobial efficacy of CHX is increased in vitro by
adding 5% dexpanthenol. Since the combination achieves
an antimicrobial efficacy of ≥3 log during a real-life
exposure time – as required for antiseptics – the CHX-
based wound creammeets the requirements for a wound
antiseptic. However, also other antimicrobial preparations
do achieve these criteria in the quantitative suspension
test, such as octenidine, polihexanide, PVP-iodine and
triclosan. Comparing the antimicrobial efficacy of these
antiseptics, CHX is superior to PVP-iodine and triclosan
and comparable to the antimicrobial efficacy of octenidine
and polihexanide after 24 hours’ exposure time [20].
Since, compared to triclosan and silver compounds, the
biocompatibility index is superior [21], CHX may be well
suited to be used as a wound antiseptic for this indication.
Furthermore, the residual efficacy of CHX is an advantage
for a wound antiseptic, which is only exceeded in-vitro by
octenidine [22]. However CHX has not been shown to
have an allergenic effect in animal experiments. In view
of the unusually widespread global use of CHX as an an-
tiseptic, the rare occurrence of allergic reactions [23]
should not be overstated.
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In some experimental models, mutations have been in-
duced by CHX. The relevance of these findings for humans
is unclear. Negative results were obtained in DNA repair
assays (umuC, SOS chromotest). The highest dose tested
without a mutagenic effect was in the mouse dominant-
lethal test 1000 mg/kg/d and in the cytogenetic test in
the hamster 250 mg/kg/d [24]. With diploid cells of
A. nidulans, a test model for the detection of carcinogenic
agents, mitotic recombination were induced by 1.5 and
10 µM CHX (in the case of CHX corresponds to
0.0001343% and 0.00089577% respectively) [25]. An
increase in chromosomal aberrations in the bonemarrow
was induced in the mouse following dermal application
of 0.2 mL 0.5% CHx solution in distilled water twice daily
for 28 days (50 mg/kg) [26]. In human lymphocytes, the
micronucleus frequency was significantly increased above
0.5 mg/mL (0.05%): viability was significantly reduced
above 0.4 mg/mL [27]. Oral administration for 14 days
in the rat induced reversible hyperkeratosis, ulceration
and dysplasia in concentrations of 0.2% and to a lesser
extent with 0.02% [28]. In the hamster, the only change
was an increase in formazan deposition in surface mu-
cosal cell layers [29]. With daily oral administration of
3 mL 0.12% CHX solution for 8 days to rats, there was a
significant increase in DNA damage (demonstrated in the
comet assay) in leukocytes and kidney cells [30]. In con-
trast, no local side effects were observed in a 2-year oral
study in human subjects [31], [32]. Nor was reproduction
toxicity identified. There was no evidence of teratogenicity,
embryotoxicity or effects on fertility with 50mg/kg/d [33],
which was confirmed by a more recent study [24] in re-
spect of fertility with up to 100 mg/g/d and in respect of
teratogenicity with up to 300 mg/kg/d.
Conclusion
As Bepanthen® Antiseptic Wound Cream achieves the
in vitro bactericidal and fungicidal efficacy required for a
wound antiseptic with three different organic challenges,
including a worst-case scenario. Taking account of recent
findings from the literature on themicrobicidal and resid-
ual effect of CHX, and bearing in mind the contraindica-
tions for CHX (allergy and anaphylaxis), the wound oint-
ment may be regarded as suitable for use as a wound
antiseptic under real challenging conditions. Themicrobi-
cidal efficacy is enhanced by the addition of 5% dexpan-
thenol, which additionally supports wound healing.
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